Fig. 5: SPVN06 DNA and RdCVF and RdCVFL mRNA expression in the retina of NHPs following SPVN06 subretinal bilateral injection. | Gene Therapy

Fig. 5: SPVN06 DNA and RdCVF and RdCVFL mRNA expression in the retina of NHPs following SPVN06 subretinal bilateral injection.

From: Preclinical safety and biodistribution of SPVN06, a novel gene- and mutation-independent gene therapy for rod-cone dystrophies

Fig. 5

Quantification of (A) SPVN06 DNA (vector genome copies, qPCR) and (B) RdCVF and (C) RdCVFL mRNA expression (RT-qPCR) in the retinal bleb and remaining retina at Week 13 post-injection with all doses of SPVN06 (N = 6 eyes). Quantification of (D) SPVN06 DNA (vector genome copies, qPCR) and (E) RdCVF and (F) RdCVFL mRNA expression (RT-qPCR) in the retinal bleb and remaining retina at Weeks 4 and 13 post-injection with SPVN06 at 6.0 × 1010 and 3.0 × 1011 vg/eye (N ≥ 4 eyes). Data shown are mean ± SEM, with each point representing an individual eye. NHP, non-human primate; qPCR, quantitative polymerase chain reaction; RdCVF, rod-derived cone viability factor; RdCVFL, rod-derived cone viability factor long-form; RT-qPCR, quantitative reverse transcription polymerase chain reaction.

Back to article page